Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Bio-Techne Corporation reports news about its global life sciences business, which supplies reagents, analytical instruments and precision diagnostics for research, biopharmaceutical, biotechnology and clinical diagnostic customers. Company updates commonly cover financial results, cash dividends, investor conference presentations and demand trends across large pharma, emerging biotech and academic markets.
Product news centers on Bio-Techne's R&D Systems™, Bio-Techne Spatial™ and Bio-Techne Diagnostics™ portfolios. Recent recurring themes include spatial biology workflow additions for the COMET™ suite, SPYRE™ antibody panels and amplification kits, GMP-grade reagents for cell and gene therapy workflows, and the Ella cartridge-based immunoassay platform for translational research and clinical applications.
Bio-Techne (NASDAQ: TECH) declared a quarterly dividend of $0.08 per share for the quarter ended March 31, 2026. The dividend is payable May 29, 2026 to shareholders of record on May 18, 2026. The Board will consider future cash dividends on a quarterly basis.
Bio-Techne reported fiscal 2025 net sales of over $1.2 billion and operates in 34 locations with about 3,100 employees.
Bio-Techne (NASDAQ: TECH) reported third quarter fiscal 2026 results for the period ended March 31, 2026. Net sales were $311.4 million, down 2% year-over-year, with organic revenue down 2% and foreign exchange +2%. GAAP EPS rose to $0.32 from $0.14; adjusted EPS was $0.53 versus $0.56. GAAP operating income increased 95% to $75.5 million and GAAP operating margin improved to 24.2% from 12.2%. Management cited continued strength in large pharma, mid-teens Spatial Biology growth, and nearly 50% GMP protein growth excluding fast-track orders.
Bio-Techne (NASDAQ: TECH) said Kim Kelderman, President and CEO, will present at the Bank of America Securities 2026 Global Healthcare Conference on Tuesday, May 12, 2026 at 9:20 a.m. PDT. A live webcast will be available via the company’s investor relations IR Calendar page.
Bio-Techne (NASDAQ: TECH) announced a streamlined brand architecture on April 16, 2026, organizing products into three portfolio brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics. The structure aligns solutions to the scientific journey from discovery to translational research to clinical diagnostics.
The portfolios debut at AACR Annual Meeting 2026 and IMMUNOLOGY2026 and aim to make it easier for scientists and clinicians to find application‑focused tools, including proteins, antibodies, spatial biology platforms, and IVD‑grade reagents.
Bio-Techne (NASDAQ: TECH) will host a conference call and webcast on Wednesday, May 6, 2026 at 8:00 a.m. CDT to review third quarter fiscal 2026 financial results.
Access details include U.S. and international dial-in numbers, conference ID TECHQ3, and a live webcast at the company investor site. A recorded replay will run from 11:00 a.m. CDT May 6 until 11:00 p.m. CDT June 6, 2026.
Bio-Techne (NASDAQ: TECH) on March 25, 2026 expanded its COMET spatial biology portfolio with new SPYRE Focus Panels (Stroma and Vessel) and SPYRE Amplification Kits. These add modular panel options, seqLA amplification for low-abundance targets, and HORIZON image-analysis enhancements to streamline hyperplex tissue workflows.
The release emphasizes increased sensitivity, faster setup, and flexibility for integrating lab antibodies across the COMET automated ecosystem to support research and preclinical studies.
Bio-Techne (NASDAQ: TECH) will present at two investor conferences in early March 2026: TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 11:10 AM EST and Leerink Partners Global Healthcare Conference on March 10, 2026 at 8:40 AM EDT. A live webcast will be available via the company's IR Calendar page.
Bio-Techne (NASDAQ: TECH) announced on Feb 16, 2026 that its Ella benchtop immunoassay platform received CE‑IVD marking and is now available for sale in the European Union. The cartridge-based system delivers biomarker results in under 90 minutes with minimal hands-on time.
The CE‑IVD mark supports Ella's use in clinical trials, in-house test development, and validated clinical applications, while Simple Plex assays remain indicated for research use only.
Bio-Techne (NASDAQ: TECH) announced leadership changes effective March 1, 2026. Dr. Matt McManus will transition from his role as President, Diagnostics and Spatial Biology Segment and will remain with the company temporarily to support a smooth transition. Steve Crouse is appointed President, Diagnostics and Spatial Biology Segment.
Steve Crouse joins from Bio-Techne's Analytical Solutions Division, brings over 20 years of industry experience, and is credited with launching platforms and delivering strong growth during his four-year tenure at Bio-Techne.
Management said McManus played a key role in organizational optimization, including the strategic divestiture of the Exosome business.
Bio-Techne (NASDAQ: TECH) announced a quarterly cash dividend of $0.08 per share for the quarter ended December 31, 2025. The dividend is payable February 27, 2026 to shareholders of record on February 16, 2026. Future dividends will be reviewed quarterly by the board.
The company reported over $1.2 billion in net sales for fiscal 2025 and has approximately 3,100 employees worldwide. The release includes standard forward-looking cautionary language about risks and uncertainties.